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Abstract
Background: (−)-Epigallocatechin gallate (EGCG) is a major polyphenol component of green tea that has
antioxidant activities. Lipopolysaccharide (LPS) induces inflammatory cytokine production and impairs blood–brain
barrier (BBB) integrity. We examined the effect of EGCG on LPS-induced expression of the inflammatory cytokines in
human cerebral microvascular endothelial cells (hCMECs) and BBB permeability.
Methods: The expression of TNF-α, IL-1β and monocyte chemotactic protein-1 (MCP-1/CCL2) was determined by
quantitative real time PCR (qRT-PCR) and ELISA. Intercellular adhesion molecule 1 (ICAM-1) and vascular cell
adhesion molecule (VCAM) in hCMECs were examined by qRT-PCR and Western blotting. Monocytes that adhered
to LPS-stimulated endothelial cells were measured by monocyte adhesion assay. Tight junctional factors were
detected by qRT-PCR (Claudin 5 and Occludin) and immunofluorescence staining (Claudin 5 and ZO-1). The
permeability of the hCMEC monolayer was determined by fluorescence spectrophotometry of transmembrane
fluorescin and transendothelial electrical resistance (TEER). NF-kB activation was measured by luciferase assay.
Results: EGCG significantly suppressed the LPS-induced expression of IL-1β and TNF-α in hCMECs. EGCG also
inhibited the expression of MCP-1/CCL2, VCAM-1 and ICAM-1. Functional analysis showed that EGCG induced the
expression of tight junction proteins (Occludin and Claudin-5) in hCMECs. Investigation of the mechanism showed
that EGCG had the ability to inhibit LPS-mediated NF-κB activation. In addition, 67-kD laminin receptor was involved
in the anti-inflammatory effect of EGCG.
Conclusions: Our results demonstrated that LPS induced inflammatory cytokine production in hCMECs, which
could be attenuated by EGCG. These data indicate that EGCG has a therapeutic potential for endotoxin-mediated
endothelial inflammation.
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Background
The brain endothelial cells interact with resident cells in
the central nervous system (CNS), providing the protect-
ive blood–brain barrier (BBB) interface between the
CNS and peripheral blood system. By controlling the ac-
cess of blood components, including immune cells to
the CNS, the BBB regulates the delicate milieu optimal
for neuronal communication and helps to maintain the
homeostasis of the CNS. Breakdown of BBB is an early
and significant event in CNS inflammation induced by
extrinsic or intrinsic stimuli, including endotoxins [1]. It
has been shown that brain endothelial cells are a pri-
mary target of immunological attack in bacterial infec-
tion, and their injury can lead to vascupathy and organ
dysfunction associated with disruption of tight junctions
in the brain endothelium [2].
Lipopolysaccharide (LPS), a product of bacterial infec-
tion, is known to induce inflammatory cytokines and
impairs the BBB system. A central feature of the patho-
physiology of acute inflammation and septic shock triggered
by LPS is the production of multiple proinflammatory
mediators such as cellular adhesion molecules, cytokines,
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and chemokines by monocytes–macrophages as well as
vascular endothelial cells [3]. LPS can directly elicit a
variety of inflammatory cytokines in endothelial cells,
such as inducible nitric oxide synthase (iNOS) [4], IL-1β
[5] and IL-6 [6,7]. Furthermore, LPS, TNF-α, or IL-1β
can significantly stimulate human brain microvascular
endothelial cells (HBMECs) to release monocyte chemo-
tactic chemotacticprotein-1 (MCP-1/CCL2), an import-
ant factor for monocyte migration bound to the apical
endothelial surfaces [8].
Intact cerebral endothelial cells constitutively express
low levels of intercellular adhesion molecule 1 (ICAM-
1), which plays a vital role in the process of leukocyte
transmigration through endothelial cell barriers and has
been shown to mediate signal transduction events in
endothelial cells induced either by its cross-linking or by
the binding of T lymphocytes [9]. However, when stimu-
lated by LPS or certain cytokines, these cells produce
high levels of ICAM-1 [10,11]. The cell walls of Strepto-
coccus pneumoniae (PCW), the most common cause of
adult bacterial meningitis, also induces ICAM-1 expres-
sion in rat primary brain microvascular endothelial cell
cultures [4]. This induction could be completely blocked
by TNF-α antibody, suggesting that ICAM-1 expression
is mediated by the inflammatory cytokine and that cere-
bral endothelial cells regulate critical steps in inflamma-
tory BBB disruption of bacterial meningitis. Therefore,
regulation of endothelial adhesion molecule and cyto-
kine expression in brain endothelial cells is critical in
maintaining BBB integrity.
(−)-Epigallocatechin gallate (EGCG), also known as
epigallocatechin 3-gallate, is the most abundant catechin
in green tea. EGCG as a potent antioxidant has been
shown to have both anti-inflammatory and anti-
atherogenic properties in experimental studies con-
ducted in vitro and in vivo [12,13]. EGCG was found to
inhibit TNF-α-induced production of MCP-1/CCL2
from bovine coronary artery endothelial cells, providing
direct vascular benefits in inflammatory cardiovascular
diseases [14]. Previous studies have also demonstrated
that EGCG attenuated the increase in malondialdehyde
levels caused by cerebral ischemia and reduced the for-
mation of post-ischemic brain edema and infarct volume
[15]. This study suggests that EGCG is a neuroprotective
agent against excitotoxicity-related neurologic disorders
such as brain ischemia. Further, the neuroprotective ef-
fect of EGCG against ischemia-induced brain damage
was found, in part, to be due to modulation of NOS iso-
forms and preservation of mitochondrial complex activ-
ity and integrity [16]. Thus, the in vivo neuroprotective
effects of EGCG are not exclusively due to its antioxi-
dant effects but involve more complex signal transduc-
tion mechanisms. In this study, we examined whether
EGCG possesses the ability to protect the endothelial
monolayer from loss of tight junction proteins and dis-
ruption of BBB permeability. We used a well-established
in vitro model of the human BBB to monitor the effects
of LPS and/or EGCG on the inflammatory responses
and barrier permeability. We also investigated the
mechanisms through which EGCG exerts its action on




EGCG (≥95%) was purchased from Sigma-Aldrich St.
Louis, MO, USA (CAS#: 989-51-5; Cat# E4143). EGCG
stock solution was prepared in sterile double distilled
water at 20 mM.
Brain endothelial cell culture
Human cerebral microvascular endothelial cell (hCMEC)
line, D3 clone, was developed by immortalization of the
primary human brain vascular endothelial cells after
transduction with lentiviral vectors encoding the cata-
lytic subunit of human telomerase hTERT and SV40 T
antigen, as described previously [17]. The hCMEC/D3
cell line recapitulates most of the unique properties of
brain endothelium and may thus constitute a well estab-
lished in vitro model of the human BBB [17]. It has also
been reported that D3 cell line maintains the in vitro
physiological permeability barrier properties of the BBB,
even in the absence of abluminal astrocytes [18]. D3
cells express typical endothelial markers (VE-cadherin
and Occudin) and have been successfully used as an
in vitro model of the BBB [19-21]. D3 cells were grown
in endothelial cell growth medium (EGMW; Lonza,
Walkersville, MD, USA) supplemented with vascular
endothelial growth factor, insulin-like growth factor-1,
epidermal growth factor, basic fibroblast growth factor,
Gentamicin, ascorbic acid, heparin, fetal bovine serum
and hydrocortisone (Lonza, Walkersville, MD, USA).
Cells were cultured on collagen-coated (BD Biosciences,
Rockville, IL, USA) tissue culture plate in a humidified
atmosphere at 37°C in 5% CO2.
Treatment of endothelial cells
hCMEC/D3 cells were treated with 100 ng/ml LPS for
different time periods (3, 6, 24, and 48 h) or with differ-
ent concentrations of LPS (1, 10, 100, and 1000 ng/ml)
for 6 h. For the pretreatment, EGCG was added to the
culture media (1, 5, and 25 μM) 1 h prior to LPS treat-
ment and further incubated together for 6 h. To test the
blockage effect of 67-kDa laminin receptor (67LR), cells
were incubated with mouse monoclonal antibody against
LR (clone MluC5; 5 μg/ml; NeoMarkers, Fermont, CA,
USA) or isotype control mouse IgM for 1 h before the
addition of EGCG to the cell cultures. To test the direct
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effect of EGCG on the expression of Toll-like receptor
(TLR)4 and Myeloid differentiation primary response
gene (88) (MyD88), hCMEC/D3 cells were treated with
5 μM of EGCG for 12 to 72 h or with 0 to 25 μM of
EGCG for 24 h.
Reverse transcription and quantitative real time PCR
Total RNA was extracted with Tri-reagent (Sigma-
Aldrich) and quantitated by spectrophotometric analysis.
Reverse transcription was performed using the AMV
transcriptase and RNasin (Promega Co., Madison, WI,
USA) according to the manufacturer’s instruction. Quan-
titative real time PCR (qRT-PCR) was performed with
Brilliant SYBR Green Master Mix (Bio-Rad Laboratories,
Hercules, CA, USA) described previously [22]. The pri-
mers that were used for the PCR amplifications are listed
in Table 1. The oligonucleotide primers were synthesized
by Integrated DNA Technologies, Inc. (Coralville, IA,
USA). All values were calculated using the delta delta Ct
method and expressed as the change relative to the
expression of glyceraldehyde 3-phosphate dehydrogen-
ase (GAPDH) mRNA.
ELISA
TNF-α, IL-1β and MCP-1/CCL2 gene expressions, iden-
tified from RT-PCR, were evaluated for protein expres-
sion using ELISA. After hCMEC/D3 cells were treated
as indicated in the figure Figure. 1 and 2, conditioned
medium was collected and levels of TNF-α, IL-1β and
MCP-1/CCL2 were measured using conventional double
sandwich ELISA kits from eBioscience Inc. (San Diego,
CA, USA). Assays were performed according to the
manufacturer's instructions.
Immunofluorescence assay
hCMEC/D3 cells were cultured on chamber slides or glass
coverslips in 24-well plate coated with collagen. After
treatment, cells were washed with ice-cold PBS (with Ca2+
and Mg2+) twice, then fixed at 4°C in 4% paraformaldehyde
plus 4% sucrose in PBS for 30 minutes. Subsequently, the
cells are permeated with 0.2% Triton X-100 in PBS on ice
for an additional 10 minutes. Cells were blocked in Block
Solution (Pierce, Rockford, IL, USA) for 1 h at room
temperature. The cells were then incubated at room
temperature with mouse anti-Claudin 5 (1:50; Invitrogen,
Grand Island, NY, USA) or mouse anti-ZO-1 (1:50; Invi-
trogen) for 1 h. After three washes with PBS, cells were
incubated with Alexa488-conjugated goat anti-mouse IgG
(1:250) for 1 h. Cells were then viewed under a fluores-
cence microscope (Olympus IX71, Japan).
Western blot analysis
The expression of the tight junctional proteins Claudin-
5 and Occludin in hCMEC/D3 was evaluated by immu-
noblot analysis. Following incubation with specific anti-
bodies and extensive washing in PBS containing 0.05%
Tween-20, membranes were incubated with horseradish
peroxidase-conjugated goat antimouse IgG (Pierce,
Chester, UK) for 1 h at room temperature. Membranes
were extensively washed in PBS containing 0.05%
Tween-20, and immunoblots were visualized by enhanced
chemiluminescence detection (ECL, Amersham, Bucks,
UK).
Monocyte adhesion assay
Endothelial hCMEC/D3 cells were plated at 104cells/well
in 200 μl clonetics medium in collagen-coated black bot-
tom 96-well plates for 3 days. Cell cultures were then
maintained in partial clonetics medium (without growth
factors) for an additional 72 h prior to the treatment
with LPS and/or EGCG. Monocytes were isolated from
peripheral blood mononuclear cells of a healthy donor
as described previously [23] at the Path Bio Resource
Human Immunology Core in accordance with protocols
Table 1 Primer sequences for the quantitative real time PCR
Gene name Forward Reverse
TNF-α 5’-CGA GTG ACA AGC CTG TAG C-3’ 5’-GGT GTG GGT GAG GAG CAC AT-3’
IL-1β 5’-AAG CTG ATG GCC CTA AAC AG-3’ 5’-AGG TGC ATC GTG CAC ATA AG-3’
MCP-1/CCL2 5’-CAT AGC AGC CAC CTT CAT TCC-3’ 5’-TCT GCA CTG AGA TCT TCC TAT TGG-3’
ICAM-1 5’-CCT TCC TCA CCG TGT ACT GG-3’ 5’-AGC GTA GGG TAA GGT TCT TGC-3’
VCAM-1 5’-GGG AGC TCT GTC ACT GTA AG-3’ 5’-ATC CGT ATC CTC CAA AAA CT-3’
Occludin 5’-AAG CAA GTG AAG GGA TCT GC-3’ 5’-GGG GTT ATG GTC CAA AGT CA-3’
Claudin 5 5’-GTC TTT ACT CCA TCG GCA GG-3’ 5’-TTT TTT TTT TTT GAG AGT TCA AAC C-3’
TLR4 5’-CAT TGC TTC TTG CTA AAT GCT G-3’ 5’-GGA TTA AAG CTC AGG TCC AGG-3’
MyD88 5’-CCG CGC TGG CGG AGG AGA TGG AC-3’ 5’-GCA GAT GAA GGC ATC GAA ACG CTC-3’
GAPDH 5’-GGT GGT CTC CTC TGA CTT CAA CA-3’ 5’-GTT GCT GTA GCC AAA TTC GTT GT-3’
GAPDH, glyceraldehyde 3-phosphate dehydrogenase; ICAM, intercellular adhesion molecule; MCP, monocyte chemotactic protein; TLR, Toll-like receptor; VCAM,
vascular adhesion molecule.
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approved by the Human Subjects Research Committee
of the University of Pennsylvania. The purity of isolated
monocytes was higher than 95%. Cell viability was
determined by trypan blue exclusion assay and mono-
cyte viability above 95% was used. Briefly, monocytes
were resuspended in serum-free DMEM at 5× 106
cells/ml and labeled with 5 μM Calcein-AM (Molecu-
lar Probes, OR, USA) at 37°C for 30 minutes. After
washing with serum-free medium twice, the monocytes
were resuspended in clonetics medium at 106 cells/ml.
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Figure 1 Effect of (−)-epigallocatechin gallate on lipopolysaccharide-induced inflammatory cytokine expression at both mRNA and
protein levels. Human cerebral microvascular endothelial cells/D3 (hCMEC/D3) were treated with or without lipopolysaccharide (LPS) at
100 ng/mL for the indicated time periods (A,D,G,J) or at indicated concentrations for 6 h (B,H) or 24 h (E,K). (C,F,I and L) hCMEC/D3 cells were
pretreated with (−)-epigallocatechin gallate (EGCG) at the indicated concentrations for 1 h prior to LPS treatment (100 ng/mL) for an additional
6 h (C,I) or 24 h (F,L). The mRNA expression was determined by quantitative real time PCR, and protein levels in the culture medium were
measured by conventional ELISA. Data are expressed as mean± SD of three different experiments (*P< 0.05, **P< 0.01, compared with no
treatment control or LPS treatment only).
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The labeled monocytes (105 cells) were then added to
the endothelial hCMEC/D3 monolayer and incubated
for 15 minutes at 37°C to allow the adhesion [24]. The
plate was then carefully rinsed twice with 1× PBS to
remove non-adherent monocytes and read on a fluor-
escent plate reader at 494/517 nm. The actual number
of adherent monocytes was determined by compar-
ing a standard plate with known numbers of labeled
monocytes.
Transendothelial diffusion
The endothelial cell permeability was assessed by deter-
mining the flux of fluorescein through the hCMEC/D3
monolayer using a procedure described elsewhere with a
slight modification [25,26]. Briefly, hCMEC/D3 cells
were plated onto collagen-coated 0.4-μm Millicell hang-
ing cell culture inserts (Millipore, MA, USA) and left to
reach confluence for 7 to 10 days with a culture media
change every 2 to 3 days. Cells were then treated with
LPS in the presence or absence of EGCG for 24 h. After
treatment, fluorescein sodium salt in clonetics medium
was loaded to the apical filter compartment to produce
an initial concentration of 1 μM. Subsequently, 100 μl
medium was removed from the basolateral compartment
after 60 minutes. The fluorescence was measured with a
fluorescence microplate reader (PerkinElmer 1420 Mul-
tilabel Counter, Bridgeville, PA, USA) at 488/525 nm.
The concentration of fluorescein sodium salt in the
lower compartment represents the endothelial mono-
layer permeability [26].
Transendothelial electrical resistance
To determine the integrity of brain endothelial mono-
layers, transendothelial electrical resistance (TEER) mea-
surements were performed using the 1600R ECIS system
(Applied Biophysics, Troy, NY, USA). The ECIS system
provides real-time monitoring of changes in TEER. Briefly,
hCMEC/D3 at 105 per well were plated on collagen type
I-coated 96W10E+ electrode arrays (Applied Biophysics).
The cells were then allowed to form monolayers reaching
stable TEER values. After 4 days (with a media change
every 2 days), the monolayers were exposed to various
concentrations of LPS with or without EGCG pretreat-
ment as indicated. The readings were acquired continu-
ously for 72 h at 4000 Hz and at 30-minute intervals.
Confluent hCMEC/D3 monolayers showed baseline TEER
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Figure 2 Effect of (−)-epigallocatechin gallate on lipopolysaccharide-induced MCP-1 expression. Human cerebral microvascular endothelial
cells/D3 (hCMEC/D3) were treated with 100 ng/mL of lipopolysaccharide (LPS) for the indicated time periods (A,D) or with LPS at the indicated
concentrations for 6 h (B) or 24 h (E). (C,F) hCMEC/D3 cells were pretreated with (−)-epigallocatechin gallate (EGCG) at the indicated
concentrations for 1 h prior to LPS treatment (100 ng/mL) for an additional 6 h (C) or 24 h (F). The mRNA expression was determined by
quantitative real time PCR and protein levels in the culture medium were measured by conventional ELISA. Data are expressed as mean± SD of
three different experiments (*P< 0.05, **P< 0.01, compared with no treatment control or LPS treatment only).
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as a percentage change of baseline TEER along with the
standard error of the mean of condition replicates.
Transfection and luciferase assays
The plasmid (pNF-κB-Luc) containing NF-κB pro-
moter linked with a luciferase gene was developed by
Dr Petrak [27]. Two copies of the mouse k light
chain enhancer [28] were cloned into pBLCAT3 vec-
tor [29], and then the construct was modified by re-
placing the CAT reporter with the luciferase gene
obtained from pGEM-Luc plasmid [27]. DNA was
prepared by Miniprep techniques, according to the
manufacturer’s instruction (Qiagen, Valencia, CA,
USA) and used in the transfection experiments. For
each transfection experiment, the hCMEC/D3 cells
were seeded in a 12-well tissue culture plate at a
density of 3 × 105 cells/well 1 day before transfection.
The cells were transfected with the pNF-κB-Luc using
FuGene HD Transfection Reagent (Roche Molecular
Bilchemicals, Indianapolis, IN, USA) with a ratio of
FuGene HD : plasmid 3:1 (μl:μg). Six hours after the
transient transfection, the cells were incubated with or
without EGCG (1, 5, and 25 μM) for 1 h, then trea-
ted with LPS for an additional 6 h. At the termin-
ation of the experiments, cells were washed twice
with PBS, then lyzed in 0.1 ml 1× Cell Culture Lysis
Buffer (Promega, Madison, WI, USA). Cell-free lysates
were obtained by centrifugation at 13,000 × g for 2
minutes at 4°C. The effects of LPS/EGCG on the activa-
tion of NF-κB promoter in these transiently transfected
cells were determined by NF-κB promoter-driven lucifer-
ase activity. Luciferase activity in cell lysate was quantified
using a luciferase assay system (Promega) and a lumin-
ometer. The results were presented as relative light units
and data were expressed as -fold of untreated cells. Mea-
surements were performed by calculating the average of
triplicate samples of two independent experiments.
Statistically analysis
Data are expressed as the mean± SD of at least three inde-
pendent experiments. Statistical significance was analyzed
using a one-way analysis of variance (ANOVA) followed
by post Newman-Keul’s test. It was considered statistically
significant when the P-value was less than 0.05.
Results
(−)-Epigallocatechin gallate inhibits lipopolysaccharide-
mediated induction of inflammatory cytokine expression
We first investigated the effect of LPS on the inflam-
matory cytokine (TNF-α and IL-1β) expression in
hCMEC/D3 cells. As shown in Figure 1, LPS treatment
of hCMEC/D3 cells significantly induced the expres-
sion TNF-α and IL-1β at both mRNA (Figure 1A,B,G,
H) and protein (Figure 1D,E,J,K) levels. The highest
effect of LPS on these cytokines at the mRNA level
was observed at 3 h post-treatment and diminished as
time went by (Figure 1A,G). The induction of these
cytokines at the mRNA and protein levels were both
time- and dose-dependent (Figure 1B,D,E,H,J,K). EGCG
pretreatment of hCMEC/D3 cells could compromise
the induction effect of LPS on the cytokines at both
the mRNA and protein levels (Figure 1C,F,I,L).
(−)-Epigallocatechin gallate inhibits lipopolysaccharide-
induced expression of monocyte chemotactic protein and
adhesion molecule
Endothelial cells express MCP and adhesion molecules
that mediate the interactions between cells of the
immune system and the endothelium system. We
found that LPS treatment of hCMEC/D3 cells induced
the expression of MCP-1 in both time-dependent
(Figure 2A,D) and dose-dependent (Figure 2B,E) fash-
ions. EGCG pretreatment at 5 and 25 μM significantly
inhibited the upregulation of MCP-1 by LPS treatment
(Figure 2C,F). In addition, LPS could time- and dose-
dependently induce the mRNA expressions of two ad-
hesion molecules, ICAM-1 (Figure 3A,B) and vascular
adhesion molecule (VCAM)-1 (Figure 3D,E). The in-
duction of ICAM-1 and VCAM-1 by LPS was also
observed at the protein level as determined by western
blotting (Figure 3G). It was found that 6 h stimulation
was enough to potently induce the protein expression
of ICAM-1 and VCAM-1 (Figure 3G), with no signifi-
cant increase when the treatment was extended to
24 h or 48 h. Therefore, we used 6 h stimulation when
performing monocyte adhesion experiments. We next
examined whether EGCG pretreatment of hCMECs
could attenuate the expression of ICAM-1 and VCAM-
1. We observed that EGCG pretreatment of hCMEC/
D3 cells inhibited LPS-mediated induction of ICAM-1
and VCAM-1 at both the mRNA (Figure 3C,F) and
protein levels (Figure 3H).
(−)-Epigallocatechin gallate inhibits lipopolysaccharide-
mediated monocyte adhesion to endothelial cells
Since MCP-1, ICAM-1 and VCAM-1 are the key ele-
ments in mediating the adhesion of leukocytes to vas-
cular endothelia, we investigated the effect of EGCG
on monocyte adhesion to hCMEC/D3 cells. Figure 4A
shows that LPS treatment of hCMEC/D3 significantly
increased monocyte adhesion to the endothelial cell
monolayer. This LPS effect was in a dose-dependent
manner (Figure 4B). EGCG alone has little effect on
monocyte adhesion whereas EGCG pretreatment of
hCMEC/D3 cells attenuated LPS-induced adhesion of
monocytes to the endothelial monolayer (Figure 4A,B).
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(−)-Epigallocatechin gallate blocks lipopolysaccharide-
mediated suppression of Claudin 5 and Occludin
The tight junctional proteins, mainly Claudins and
Occludins, are closely associated with the integrity of the
BBB. We therefore examined the effect of EGCG on
LPS-induced expression of these proteins. As shown in
Figure 5A and B, LPS treatment suppressed the expres-
sion of Claudin 5 and Occludin in hCMEC/D3 cells at
the mRNA level. This LPS effect, however, was inhibited
in a dose-dependent fashion by EGCG pretreatment
(Figure 5A, B). As it has been reported that Occludin
was not consistently detected at cell-cell contacts of
hCMEC/D3 cells [17], we only examined the protein ex-
pression of Claudin 5 and ZO-1 in hCMEC/D3 cells by
immunofluorescence assay. Figure 5C and D shows that
the LPS treatment compromised the expression of these
two junctional proteins while EGCG pretreatment could
protect the loss of Claudin 5 and ZO-1 at the cell-cell
contacts.
(−)-Epigallocatechin gallate protects blood–brain barrier
permeability compromised by lipopolysaccharide
treatment
We next examined the effect of LPS with or without
EGCG pretreatment on the BBB permeability. As shown
in Figure 6A, LPS treatment enhanced the diffusion
of sodium fluorescein across the hCMEC/D3 mono-
layer to the basal compartment, while the pretreatment
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Figure 3 Effect of (−)-epigallocatechin gallate on lipopolysaccharide-induced adhesion molecule expression of endothelial cells. (A-F)
Human cerebral microvascular endothelial cells/D3 (hCMEC/D3) were treated with 100 ng/ml of lipopolysaccharide (LPS) for the indicated time
periods (3, 6, 24, 48 h) or with LPS at the indicated concentrations for 6 h. For pretreatment, cells were treated with (−)-epigallocatechin gallate
(EGCG) (1, 5, and 25 μM) for 1 h prior to LPS treatment. The mRNA expression was determined by quantitative real time PCR. Data are expressed
as mean± SD of three different experiments (*P< 0.05, **P< 0.01, compared with no treatment control or LPS treatment only). (G) Cells were
treated with 100 ng/ml of LPS for the indicated time periods and protein was extracted for western blotting of adhesion molecule expression. (H)
hCMEC/D3 cells were treated with EGCG for 1 h prior to LPS treatment for 6 h. Protein was extracted for western blotting of adhesion molecule
expression. Representative data from three independent experiments are shown.
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with EGCG reduced LPS-mediated diffusion of sodium
fluorescein in the hCMEC/D3 cells (Figure 6A). hCMEC/
D3 cells form a relative low TEER across the mono-
layer as compared with primary human brain micro-
vascular endothelial cells [30]. Figure 6A shows that
LPS treatment reduced the TEER of the hCMEC/D3
monolayer while EGCG pretreatment retains the TEER
at a comparatively high level. Thus, EGCG has protec-



















































Figure 5 Effect of (−)-epigallocatechin gallate on the expression of Claudin-5/Occludin of human cerebral microvascular endothelial
cells/D3. Human cerebral microvascular endothelial cells/D3 (hCMEC/D3) were pretreated with (−)-epigallocatechin gallate (EGCG) at the
indicated doses for 1 h prior to lipopolysaccharide (LPS) treatment (100 ng/mL) for 24 h. RNA extracted was subjected to real time PCR for
Claudin-5 and Occludin expression (A,B). Data are expressed as mean± SD of three independent experiments. (C) hCMEC/D3 cells were
pretreated with 5 μM EGCG for 1 h and then with 100 ng/ml LPS for 24 h. Cells were fixed and then incubated with anti-Claudin 5 or anti-ZO-1


























Figure 4 Effect of (−)-epigallocatechin gallate on lipopolysaccharide-induced monocyte adhesion to endothelial cells. (A) Human
cerebral microvascular endothelial cells/D3 (hCMEC/D3) were pretreated with or without (−)-epigallocatechin gallate (EGCG) (25 μM) for 1 h prior
to lipopolysaccharide (LPS) (100 ng/mL) treatment for an additional 6 h. Calcein-AM-labeled fresh monocytes were then added to hCMEC/D3 cell
cultures and incubated for 15 minutes at 37°C. The fluorescence was measured at 494/517 nm and the actual numbers of adherent monocytes
were determined by comparing a standard plate with known numbers of labeled monocytes. (B) hCMEC/D3 cells were treated with LPS at the
indicated concentrations for 6 h, or EGCG (1, 5, 25 μM) for 7 h, or pretreated with EGCG (1, 5 or 25 μM) for 1 h followed by LPS treatment
(100 ng/mL) for 6 h. Data are expressed as mean± SD of three different experiments (*P< 0.05, **P< 0.01).
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(−)-Epigallocatechin gallate inhibits lipopolysaccharide-
induced NF-κB activation
NF-κB is a key transcription factor for regulating the im-
mune response to bacterial or viral infections. Dysregu-
lations of NF-κB are associated with inflammatory and
autoimmune diseases, viral infections and improper
immune responses [31]. As shown in Figure 7, LPS
treatment of hCMEC/D3 cells induced the activation of
NF-κB. When the cells were pretreated with 25 μM
EGCG, LPS-induced NF-κB activity was attenuated
from 20-fold to 8-fold (Figure 7), while EGCG alone
had little effect on NF-κB activation or inhibition (data
not shown).
67-kDa laminin receptor is involved in
(−)-epigallocatechin gallate-mediated suppression of
lipopolysaccharide-mediated inflammatory cytokine
induction
67LR, a cell-surface receptor for EGCG, has been shown
to be involved in the EGCG-mediated inhibitory effect
on the TLR4 signaling pathway in macrophages [32]. We
therefore examined whether EGCG acts through 67LR
on the inhibition of LPS-mediated inflammation. We
found that, when hCMEC/D3 cells were pretreated with
neutralization antibody to 67LR prior to EGCG and LPS
treatment, the inhibitory effect of EGCG on LPS-
induced inflammatory cytokine expression was abrogated
(Figure 8A,B). The blockage of 67LR also attenuated the
inhibitory effect of EGCG on LPS-mediated NF-κB acti-
vation (Figure 8C) and increased fluorescein sodium
transmembrance diffusion (Figure 8D). EGCG alone had
little effect on the expression of TLR4 and MyD88
(Figure 9).
Discussion
In the present study, we demonstrated that EGCG, a
bioactive polyphenol in green tea, suppressed the ex-
pression of LPS-induced inflammatory cytokines in brain
endothelial cells. This finding supports a previous report
showing that EGCG attenuated LPS-mediated inflamma-
tion by suppressing the TNF-α and IL-1β expression in



























































Figure 6 Effect of (−)-epigallocatechin gallate on the permeability of human cerebral microvascular endothelial cells/D3. (A) Human
cerebral microvascular endothelial cells/D3 (hCMEC/D3) were cultured in 0.4-μm Millicell hanging cell culture inserts to become confluent and
then treated with lipopolysaccharide (LPS) (100 ng/mL) in the presence or absence of (−)-epigallocatechin gallate (EGCG) at the indicated doses
for 24 h. After treatment, fluorescein sodium salt was loaded to the apical filter compartment (1 μM) and the fluorescence in the basolateral
compartment was measured within 1 h. (*P< 0.05, **P< 0.01). (B) hCMEC/D3 at 1× 105 per well were plated on collagen type I-coated
96W10E+ electrode arrays (Applied Biophysics). The cells were then allowed to form monolayers reaching stable transendothelial electrical
resistance (TEER) values. After 4 days (with a media change every 2 days), the monolayers were exposed to various concentrations of LPS with or
without EGCG pretreatment at the indicated concentrations. The readings were acquired by the 1600R ECIS system continuously for 48 h at






























Figure 7 Effect of (−)-epigallocatechin gallate on
lipopolysaccharide-induced NF-κB activation. Human cerebral
microvascular endothelial cells/D3 (hCMEC/D3) were transfected
with pNF-κB-Luc plasmid and then treated with lipopolysaccharide
(LPS) (1, 10, 100, or 1000 ng/mL) or (−)-epigallocatechin gallate
(EGCG) (1, 5, or 25 μM) for 7 h. For pretreatment, cells were treated
with EGCG (1, 5 or 25 μM) for 1 h prior to LPS treatment. Cells were
lysed and the lysate was analyzed using a luciferase assay system.
NF-κB promoter-driven luciferase activity was expressed as -fold of
untreated cells (designated as 1). Data are expressed as mean± SD
of triplicates of two independent experiments. (*P< 0.05, **P< 0.01).
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EGCG pretreatment also inhibited the monocyte ad-
hesion to the brain endothelial cell monolayer and
blocked the negative impact of LPS on the tight junc-
tional protein expression in brain endothelial cells.
MCP-1/CCL2 plays a critical role in the recruitment of
leukocytes to the site of inflammation elicited by LPS
[33]. It has been reported that EGCG could decrease
the MCP-1 and CCR2 gene expression, together with
MCP-1 secretion and CCR2 expression at the cell sur-
face in THP-1 monocytes, thus preventing the migra-
tion and adhesion of monocytes to fibronectin [34].
Our data showed that in unstimulated hCMEC/D3
cells, the basal expression of MCP-1/CCL2 was low
but measurable, while LPS treatment greatly induced
the expression of MCP-1/CCL2. This is consistent with
a previous report [35] showing that hCMEC/D3 cells
express lower levels of MCP-1/CCL2 than two primary
human brain endothelial cells generated from multiple
sclerosis brain tissue or from temporal lobe resections
from epileptic patients.
In addition, we found that LPS treatment of hCMECs
induced the expression of ICAMs and VCAMs, the key
ligands for the beta2 integrin molecules present on leu-
kocytes [36]. The expression of ICAM-1 in hCMEC/D3
cells is higher than that of VCAM-1 [17]. ICAM-1 and
VCAM-1 facilitate the adhesion of monocytes to the
endothelium. Endothelial ICAM-1 was shown to be es-
sential for T cell diapedesis across the BBB in vitro
under static conditions [37]. Adamson and colleagues
[38] revealed that endothelial ICAM-1 was essentially
involved in lymphocyte migration through brain endo-
thelial cell monolayers by rearrangement of the endo-
thelial actin cytoskeleton and functional endothelial cell
Rho proteins. Treatment of HBMEC with TNF-α
resulted in increased polymorphonuclear leukocyte




































































































































































































Figure 8 Effect of 67-kDa laminin receptor neutralization on (−)-epigallocatechin gallate-mediated inhibition of lipopolysaccharide
actions. (A,B) Effect of 67-kDa laminin receptor (67LR) antibody on (−)-epigallocatechin gallate (EGCG)-mediated suppression of the induction of
TNF-α and IL-1β by lipopolysaccharide (LPS). Human cerebral microvascular endothelial cells/D3 (hCMEC/D3) were treated with antibody against
67LR (5 μg/ml) or control IgM for 1 h prior to LPS and/or EGCG treatment. RNA extracted was subjected to real time PCR for TNF-α and IL-1β
expression. (C) Effect of 67LR antibody on EGCG-mediated inhibition of the induction of NF-κB activity by LPS. Cells were transfected with
pNF-κB-Luc plasmid and then treated with antibody against 67LR (5 μg/ml) or control IgM for 1 h prior to LPS and/or EGCG treatment for an
additional 6 h. Luciferase activity was measured in the cell lysates. (D) Effect of 67LR antibody on EGCG-mediated suppression of transmembrane
diffusion by LPS. The cells were treated with 67LR antibody, EGCG and LPS as described above. The apical apartment was then loaded with
fluorescin sodium salt and the fluorescence in the basal apartment was measured within 1 h. Data are expressed as mean± SD of three
independent experiments. (*P< 0.05, **P< 0.01, compared with LPS treatment only).
Li et al. Journal of Neuroinflammation 2012, 9:161 Page 10 of 13
http://www.jneuroinflammation.com/content/9/1/161
antibodies to E-selectin and ICAM-1, but not VCAM-1
[39].
It is well known that NF-κB activation is required
for the LPS-induced inflammatory cytokine production
[40]. Endothelial-selective blockade of NF-κB activation
repressed expression of multiple endothelial adhesion
molecules and reduced neutrophil infiltration into mul-
tiple organs [41]. EGCG was found to have the ability to
block NF-κB activation in the intestinal epithelial cell
line IEC-6 [42]. In addition, theaflavin-3,3’-digallate (an-
other polyphenol) from black tea was also reported to
have even stronger suppression of LPS-induced NF-κB
activity than other polyphenols through downregulation
of IκB kinase activity in macrophages [43]. Thus, the
suppression of NF-κB activation by EGCG justifies the
inhibitory effect of EGCG on LPS-mediated endothelial
inflammation.
It is known that TLR4 is involved in LPS-mediated in-
flammation. Sheth and colleagues [44] showed that LPS
disrupts tight junctions in cholangiocyte monolayers by a
c-Scr-, TLR4- and LBP-dependent mechanism. A recent
report [32] showed that EGCG downregulated inflamma-
tory responses by directly suppressing TLR4 mRNA and
protein expression. In addition, EGCG treatment of
macrophages was found to upregulate the expression of
Tollip [32], a negative regulator of the TLR signaling
pathway. However, our data demonstrated that EGCG
had little effect on TLR4 expression in brain endothelial
cells. Youn and colleagues [45] reported that EGCG
could inhibit LPS- or PolyI:C-mediated activation of
interferon regulatory factor 3. EGCG could modulate
both MyD88- and TIR-domain-containing adapter-indu-
cing interferon-(TRIF)-dependent signaling pathways of
TLR3 and the subsequent inflammatory target gene ex-
pression in macrophages. However, we did not observe a
modulatory effect of EGCG on the expression of MyD88,
a key adaptor to mediate the TLR-MyD88-dependent sig-
naling pathway. These discrepancies may be due to the
different types of cells used to investigate EGCG activity,
suggesting that other mechanisms are likely to be
involved in EGCG-mediated inhibition of endothelial
inflammation.
67LR is a receptor that presents on the eukaryotic cell
membrane for the cellular prion proteins and also inter-
acts with extracellular matrix components [46]. 67LR was
also found to express on both rodent and human cerebral
endothelial cells [47]. It has been suggested that 67LR
serves as a co-receptor for bacterial pathogens that target
the BBB. 67LR on brain endothelial cells interacts with
three most commonly neuroinvasive bacteria: pneumo-
coccus, H. influenzae, and meningococcus. The binding of
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Figure 9 Effect of (−)-epigallocatechin gallate on the TLR4 and MyD88 expression. Human cerebral microvascular endothelial cells/D3
(hCMEC/D3) were treated with or without 5 μM of (−)-epigallocatechin gallate (EGCG) for the indicated time periods (A,C) or with EGCG at the
indicated concentrations for 24 h (B,D). RNA extracted was subjected to real time PCR for TLR4 and MyD88 mRNA. Data are expressed as
mean± SD of three independent experiments.
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with the BBB and promote their CNS tropism, inducing
cell signaling through the other receptors, such as the
TLRs. The interaction of TLRs with 67LR may synergistic-
ally promote bacterial adherence and invasion of BBB
[47]. Interestingly, 67LR was shown to be involved in the
inhibitory effect of EGCG on the TLR4 signaling pathway
in macrophages [32]. These findings promoted our in-
terest in examining the role of 67LR in the anti-
inflammatory effect of EGCG in brain endothelial cells.
Our data that pretreatment of hCMEC cells with anti-
67LR antibody significantly blocked the EGCG effect on
LPS-mediated TNF-α and IL-1β induction, as well as on
NF-κB activation, indicate that EGCG exerts its anti-
inflammatory effect in endothelial cells at least partially
through 67LR. It is likely that pretreatment of hCMEC/D3
cells with EGCG enables the binding of 67LR to EGCG
and disrupts or modulates LPS interaction with 67LR. It
has been suggested this disruption or modulation might
engender unexpectedly broad protection against systemic
infections [47]. Thus, our data support the notion that
EGCG can be used as a potential therapeutic compound
to treat CNS inflammation related to the BBB.
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